Mckesson CORP 10-Q quarterly reports

McKesson Corporation's Q1 2027 results show an 8% increase in revenue to $105.4 billion, driven by strong performance in its North American Pharmaceutical and Oncology & Multispecialty segments, despite a dip in diluted EPS.

McKesson Corporation announced significant revenue and profit increases for the third quarter and first nine months of fiscal 2026, driven by strategic acquisitions and market growth.

McKesson Corporation announced significantly increased revenues, net income, and diluted EPS for the second quarter and first half of fiscal 2026, driven by market growth and strategic acquisitions.

McKesson Corporation reported a 14% decline in net income for the first fiscal quarter of 2026, primarily due to a significant bad debt provision related to Rite Aid's second bankruptcy filing, despite robust revenue growth.

McKesson's Q3 results show strong revenue growth driven by the U.S. Pharmaceutical segment, but earnings are impacted by divestiture-related charges and restructuring initiatives.

McKesson's Q2 results show a revenue increase but a significant drop in net income due to restructuring charges and a divestiture.

McKesson Corporation's first quarter results show a revenue increase but a slight decrease in earnings per share, impacted by opioid litigation charges and strategic restructuring.

McKesson Corporation's Q3 results show a revenue increase but a decrease in profits, influenced by a significant bad debt provision and discrete tax benefits.